• Zylox-Tonbridge and GL Capital will invest approximately HKD 1.48 billion in newly issued LifeTech shares, securing a 16.7% stake through Lighthouse Two.
• Lighthouse Two will become LifeTech’s largest single shareholder; Zylox-Tonbridge will invest approximately HKD 889 million for 60% of the investment vehicle.
• GL Capital will subscribe for 39,800,000 newly issued Zylox-Tonbridge shares at HKD 22 each, representing approximately 10.8% of enlarged share capital.
• The subscription price represents a 13.5% premium to the announcement-day closing price; proceeds will support potential LifeTech investments and international business development.
• A potential merger with LifeTech is also planned to build an integrated vascular and structural heart intervention platform in China.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zylox-Tonbridge Medical Technology Co .Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611061240PR_NEWS_USPR_____CN91426) on November 06, 2026, and is solely responsible for the information contained therein.